About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
ARWR - Arrowhead Pharmaceut...| Previous Close | $80.63 | Open | $80.61 |
| Volume | 130.6K | Market Cap | 8.696B |
| Yield | Last Dividend |
| Arrowhead Pharmaceuticals Files IND to B... | 03/01/21 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead submitted an IND to the U.S. Food and Drug Administration for ARO-APOC3, an RNAi therapeutic fo... | |
| Global Hepatitis B Virus (HBV) Market Re... | 02/24/21 |
| DUBLIN, Feb. 24, 2021 /PRNewswire/ -- The "Global Hepatitis B Virus (HBV) Market: 10 Year Demand Forecast & Impact of COVID-19 (2021-2030)" report has... | |
| FXNEWS24 |Arrowhead Pharmaceuticals Reac... | 02/22/21 |
| Arrowhead Pharmaceuticals Reaches Analyst Target Price | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News | |
| The Daily Biotech Pulse: DermTech Soars ... | 02/11/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X... | |
| Insider Selling: Arrowhead Pharmaceutica... | 02/10/21 |
| Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) General Counsel Patrick O???brien sold 90,000 shares of the business???s stock in a transaction dated Mo... | |
| RBC Capital Stick to Their Buy Rating fo... | 02/08/21 |
| RBC Capital Stick to Their Buy Rating for Arrowhead Pharmaceuticals | |
| Arrowhead Pharmaceuticals Files IND for ... | 01/25/21 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead files IND for ARO-ANG3 to start Phase 2b study in patients with mixed dyslipidemia | |
| Arrowhead Pharmaceuticals to Webcast Fis... | 01/19/21 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to release earnings and hold conference call on February 4 2021 | |
| Arrowhead Pharmaceuticals, Inc. (NASDAQ:... | 01/16/21 |
| Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski sold 13,038 shares of the company???s stock in a transaction on Tuesday, Ja... | |
| B.Riley Financial Stick to Their Buy Rat... | 01/12/21 |
| B.Riley Financial Stick to Their Buy Rating for Arrowhead Pharmaceuticals | |
| Insider Selling: Arrowhead Pharmaceutica... | 01/11/21 |
| Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski sold 30,625 shares of the company???s stock in a transaction on Wednesday, ... | |
| Arrowhead Pharmaceuticals, Inc. (NASDAQ:... | 01/10/21 |
| Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) General Counsel Patrick O???brien sold 25,000 shares of the firm???s stock in a transaction on Wednesday... | |
| Arrowhead Pharmaceuticals, Inc. (NASDAQ:... | 01/08/21 |
| Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) SVP James C. Hamilton sold 19,375 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesd... | |
| Insider Selling: Arrowhead Pharmaceutica... | 01/05/21 |
| Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Douglas B. Given sold 4,000 shares of the business???s stock in a transaction that occurred on ... | |
| Arrowhead Pharmaceuticals Reports Induce... | 12/07/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) | |
| Arrowhead Pharmaceuticals Announces Clos... | 11/25/20 |
| Arrowhead completes collaboration and license agreement with Takeda Pharmaceutical Company Limited | |
| Hepatitis B Infection Market 2020: Indus... | 11/25/20 |
| Data Bridge Market Research has recently added a concise research on the Hepatitis B infection Market to depict valuable insights related to significa... | |
| Arrowhead Pharmaceuticals Reports Fiscal... | 11/23/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced financial results for its fiscal year ended September 30, 2020 | |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) ... | 11/20/20 |
| Smith Barney Citigroup started coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a report released on Thursday, The Fly reports. The fi... | |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) ... | 11/19/20 |
| Equities research analysts at Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell started coverage on shares of Arrowhead Pharmace... | |
| Robert W. Baird Raises Arrowhead Pharmac... | 11/19/20 |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its target price hoisted by Robert W. Baird from $70.00 to $75.00 in a research note published on Monday m... | |
| Arrowhead Presents New Clinical Data on ... | 11/13/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced positive clinical data from multiple product candidates in its cardiometabolic pipeli... | |
| Arrowhead Interim Clinical Data Demonstr... | 11/13/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced positive interim clinical data at The AASLD Liver Meeting Digital Experience | |
| Arrowhead Pharmaceuticals to Participate... | 11/09/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will Participate in multiple Upcoming November 2020 Conferences | |
| Arrowhead Pharmaceuticals to Host Key Op... | 11/04/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead will host KOL webinars on two investigational RNAi based cardiometabolic candidates ARO-APOC3 a... | |
| Arrowhead Pharmaceuticals to Webcast Fis... | 11/02/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will webcast its fiscal 2020 year end earnings | |
| Insider Selling: Arrowhead Pharmaceutica... | 10/24/20 |
| Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski sold 29,166 shares of Arrowhead Pharmaceuticals stock in a transaction dated ... | |
| Analysts Anticipate Arrowhead Pharmaceut... | 10/24/20 |
| Equities research analysts expect that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will post sales of $38.62 million for the current quarter, Zacks re... | |
| Arrowhead Pharmaceuticals Inc (NASDAQ:AR... | 10/24/20 |
| Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 100,000 shares of the firm???s stock in a transaction on Friday, Oct... | |
| Christopher Richard Anzalone Sells 100,0... | 10/23/20 |
| Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 100,000 shares of the firm???s stock in a transaction on Friday, Oct... | |
| Buy rating | 02/08/21 |
| B. Riley FBR maintains Buy rating and raises Price Target from $98.00 to $106.00 | |
| Buy rating | 02/05/21 |
| Chardan Capital maintains Buy rating and raises Price Target from $81.00 to $97.00 | |
| Buy rating | 02/05/21 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $90.00 to $95.00 | |
| Strong Buy rating | 02/05/21 |
| Piper Sandler maintains Overweight rating and raises Price Target from $90.00 to $99.00 | |
| Date | 2021-02-04 (AMC) | Est. (EPS/Rev.) | $0.17/ 86.69M |
| Actual (EPS/Rev.) | $-0.20/ $21.30 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Value Investing | Flying Colors | 88.00 % | Subscribe |
| Long Only Biotech/Pharma | Biotech Buys | 33.00 % | Follow |
| Optioneering-W | Sam Allen | 27.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
